Organism Function
Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge
Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development
Beam Therapeutics Reports Promising Early Results in Sickle Cell Disease Base Editing Therapy, Despite Conditioning-Related Fatality
Beam Therapeutics, Sickle Cell Disease, Base Editing, Gene Therapy, BEAM-101, ESCAPE, Conditioning, Patient Death
Thermo Fisher Forecasts Revenue Growth in 2025 Amid Easing Market Challenges
Thermo Fisher Scientific, revenue forecast, 2025 growth, easing headwinds, biotech funding, pharmaceutical sector, laboratory products, analytical instruments.
Forbion Secures Over €2 Billion in Largest Fundraising to Date, Supporting 30 Biotechs
Forbion, venture capital, life sciences, fundraising, biotechs, Forbion Growth Opportunities Fund III, Forbion Ventures Fund VII
FDA Halts Kezar’s Lupus Nephritis Trial Due to Safety Concerns Following Four Patient Deaths
FDA, Kezar Life Sciences, lupus nephritis, zetomipzomib, clinical hold, patient deaths, safety concerns
Kezar Life Sciences Suspends Enrollment and Dosing in Phase 2b PALIZADE Trial Due to Safety Concerns
Kezar Life Sciences, PALIZADE trial, zetomipzomib, lupus nephritis, safety concerns, patient deaths, clinical trial halt
Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms
Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer
George Medicines Unveils Promising Low-Dose Triple Combination Pill for Hypertension Management
Hypertension, Triple Combination Pill, Low-Dose, Blood Pressure Control, GMRx2, George Medicines
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market